<DOC>
	<DOC>NCT01375777</DOC>
	<brief_summary>The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.</brief_summary>
	<brief_title>Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male or female ≥ 18 to ≤ 75 years of age Low density lipoprotein cholesterol (LDLC) ≥ 100 mg/dL and &lt; 190 mg/dL Framingham risk score of 10% or less Fasting triglycerides &lt; 400 mg/dL History of coronary heart disease New York Heart Association (NYHA) II IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>High cholesterol</keyword>
	<keyword>Proprotein convertase subtilisin/kexin type 9 (PCSK9)</keyword>
	<keyword>Treatment for high cholesterol</keyword>
	<keyword>Lowering cholesterol</keyword>
	<keyword>Lowering high cholesterol</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>